Dural plasmacytoma revealing multiple myeloma

2006 ◽  
Vol 104 (4) ◽  
pp. 608-610 ◽  
Author(s):  
Claire Haegelen ◽  
Laurent Riffaud ◽  
Marc Bernard ◽  
Beatrice Carsin-Nicol ◽  
Xavier Morandi

✓The authors describe the case of a 72-year-old woman with dural plasmacytoma revealing an immunoglobulin (Ig) G-kappa multiple myeloma (MM). She presented with headaches and left hemiparesis. Magnetic resonance imaging demonstrated a right frontal extraaxial lesion arising from the dura mater, and biological studies revealed hypercalcemia, hyperproteinemia, and a serum gamma globulin peak. A diagnosis of IgG-kappa MM was based on microscopic examination and immunohistochemical analysis of the dural plasmacytoma as well as on signs of systemic myeloma after surgery. The patient died 3 years after the first symptoms of MM despite systemic chemotherapy and no recurrence of the dural plasmacytoma. Myelomatous involvement of the dura mater is a rare occurrence given that only three cases have been reported to date. Nevertheless, this pathological entity should be differentiated from solitary dural plasmacytoma (SDP) because the prognosis is radically different. Progression seems to be correlated with systemic disease in contrast to the long-term survival associated with SDP. Careful systemic evaluation should be made in such a presentation to rule out MM, which would require different management and has a different prognosis.

Author(s):  
Sini Luoma ◽  
Raija Silvennoinen ◽  
Auvo Rauhala ◽  
Riitta Niittyvuopio ◽  
Eeva Martelin ◽  
...  

AbstractThe role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000–2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Median overall survival (OS) was 9.9 years for upfront-allo, 11.2 years for auto-allo, and 3.9 years for the relapse group (p = 0.015). Progression-free survival (PFS) was 2.4, 2.4, and 0.9 years, respectively (p < 0.001). Non-relapse mortality at 5 years was 8% overall, with no significant difference between the groups. Post-relapse survival was 4.1 years for upfront-allo and auto-allo, and 2.6 years for the relapse group (p = 0.066). Survival of high-risk patients was reduced. In multivariate analysis, the auto-allo group had improved OS and chronic graft-versus-host disease was advantageous in terms of PFS, OS, and relapse incidence. Late relapses occurred in all groups. Allo-SCT resulted in long-term survival in a small subgroup of patients. Our results indicate that auto-allo-SCT is feasible and could be considered for younger patients in the upfront setting.


2021 ◽  
pp. 1-6
Author(s):  
Lorena Bojalil-Alvarez ◽  
Morie A. Gertz ◽  
Elizabeth Garcia-Villaseñor ◽  
José Antonio Fernández-Gutiérrez ◽  
Oscar Alfonso Reyes-Cisneros ◽  
...  

2003 ◽  
Vol 44 (5) ◽  
pp. 749-758 ◽  
Author(s):  
Athanasios B.-T. Fassas ◽  
Frits Van Rhee ◽  
Guido Tricot

2014 ◽  
Vol 167 (4) ◽  
pp. 563-565 ◽  
Author(s):  
Craig B. Reeder ◽  
Donna E. Reece ◽  
Vishal Kukreti ◽  
Joseph R. Mikhael ◽  
Christine Chen ◽  
...  

2003 ◽  
Vol 39 (1) ◽  
pp. 31-37 ◽  
Author(s):  
A Riccardi ◽  
O Mora ◽  
C Tinelli ◽  
C Porta ◽  
M Danova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document